|
{{customText[Find out how you can bring a treatment option to your patients|Provide your patients with a treatment option today]}}
|
| |
 |
| |
|
|
| The Power of BIKTARVY®, Ready in Your Office
|
BIKTARVY combines the DESCOVY®
(FTC/TAF)* backbone with bictegravir, a
novel and unboosted INSTI1,2
|
|
| |
|
|
| INDICATION |
| BIKTARVY is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing ≥25 kg who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known resistance to any component of BIKTARVY. |
| |
|
|
| |
| IMPORTANT SAFETY INFORMATION |
| BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B |
 |
Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted. |
| |
Please see below for additional Important Safety Information for BIKTARVY.
|
|
| Dear {{customText[Dr.|Mr.|Mrs.|Ms.|]}} {{accFname}} {{accLname}}, {{customText[MD,|DO,|PharmD,|PA,|NP,|]}} |
{{customText[I would like to set up some time to talk about BIKTARVY and discuss how the BIKTARVY TODAY sampling program works.|Hope to connect with you in the near future to discuss BIKTARVY and the BIKTARVY TODAY sampling program.|I would like to connect with you about BIKTARVY and share details about the sampling program that can help bring BIKTARVY to your office.|I would like to take this opportunity to provide an introduction to the BIKTARVY TODAY sampling program.]}}
Please click to view full Prescribing Information for BIKTARVY and DESCOVY, including BOXED WARNINGS.
|
| IMPORTANT SAFETY INFORMATION (cont’d) |
| Contraindications |
| |
|
Coadministration: Do not use BIKTARVY with dofetilide or rifampin. |
| |
|
| BIKTARVY TODAY™ allows appropriate treatment-naïve and virologically suppressed patients to get started on BIKTARVY
|
| |
|
|
BIKTARVY TODAY™ allows appropriate patients who are newly diagnosed to begin treatment at the earliest opportunity.
|
| |
|
|
With BIKTARVY TODAY™, clinically appropriate patients can switch to BIKTARVY with a free sample.
|
|
| |
| |
|
Prior to or when initiating: Test patients for HBV infection |
| |
|
Prior to or when initiating, and during treatment: As clinically appropriate, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, assess serum phosphorus |
| |
 |
Please contact me if you would like to schedule a meeting to discuss the BIKTARVY TODAY™ program |
|
|
| IMPORTANT SAFETY INFORMATION |
| |
| BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B |
| |
|
Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted. |
| |
| Contraindications |
| |
|
Coadministration: Do not use BIKTARVY with dofetilide or rifampin. |
| |
| Warnings and precautions |
| |
|
Drug interactions: See Contraindications and Drug Interactions sections. Consider the potential for drug interactions prior to and during BIKTARVY therapy and monitor for adverse reactions. |
Please see below for additional Important Safety Information for BIKTARVY. |
|
|
|
| |
IMPORTANT SAFETY INFORMATION (cont’d) |
| |
| Warnings and precautions |
| |
|
Drug interactions: See Contraindications and Drug Interactions sections. Consider the potential for drug interactions prior to and during BIKTARVY therapy and monitor for adverse reactions. |
| Warnings and precautions (cont’d) |
| |
|
|
Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported. |
|
New onset or worsening renal impairment: Cases of acute renal failure and Fanconi syndrome have been reported with the use of tenofovir prodrugs. In clinical trials of BIKTARVY, there have been no cases of Fanconi syndrome or proximal renal tubulopathy (PRT). Do not initiate BIKTARVY in patients with estimated creatinine clearance (CrCl) <30 mL/min. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue BIKTARVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. |
| |
Renal monitoring: Prior to or when initiating BIKTARVY and during therapy, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, assess serum phosphorus. |
|
Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue BIKTARVY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations. |
| |
| Adverse reactions |
| |
|
Most common adverse reactions (incidence ≥5%; all grades) in clinical studies through week 144 were diarrhea (6%), nausea (6%), and headache (5%). |
| |
| Drug interactions |
| |
|
Prescribing information: Consult the full prescribing information for BIKTARVY for more information on Contraindications, Warnings, and potentially significant drug interactions, including clinical comments. |
|
Enzymes/transporters: Drugs that induce P-gp or induce both CYP3A and UGT1A1 can substantially decrease the concentration of components of BIKTARVY. Drugs that inhibit P-gp, BCRP, or inhibit both CYP3A and UGT1A1 may significantly increase the concentrations of components of BIKTARVY. BIKTARVY can increase the concentration of drugs that are substrates of OCT2 or MATE1. |
|
Drugs affecting renal function: Coadministration of BIKTARVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC and tenofovir and the risk of adverse reactions. |
| |
| Dosage and administration |
| |
|
Dosage: Patients weighing ≥25 kg: 1 tablet taken once daily with or without food. |
|
Renal impairment: Not recommended in patients with CrCl <30 mL/min. |
|
Hepatic impairment: Not recommended in patients with severe hepatic impairment. |
|
Prior to or when initiating: Test patients for HBV infection. |
|
Prior to or when initiating, and during treatment: As clinically appropriate, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, assess serum phosphorus. |
| |
| Pregnancy and lactation |
| |
|
Pregnancy: There is insufficient human data on the use of BIKTARVY during pregnancy. Dolutegravir, another integrase inhibitor, has been associated with neural tube defects. Discuss the benefit-risk of using BIKTARVY during pregnancy and conception. An Antiretroviral Pregnancy Registry (APR) has been established. Available data from the APR for FTC shows no difference in the rates of birth defects compared with a US reference population. |
|
Lactation: Women infected with HIV-1 should be instructed not to breastfeed, due to the potential for HIV-1 transmission. |
Please click to view full Prescribing Information for BIKTARVY and DESCOVY, including BOXED WARNINGS.
{{customText[I look forward to connecting with you soon and having a conversation about BIKTARVY and our sampling program.|I would like to schedule time to meet with you at your earliest convenience. Please feel free to contact me if you have any questions or would like additional information about the BIKTARVY TODAY sampling program.|If you are interested in learning more about BIKTARVY and the BIKTARVY TODAY sampling program, please reach out to set up a meeting.]}}
{{customText[Best,|Best regards,|Regards,|Sincerely,|Thanks,|Thank you,|Cheers,]}}
{{userName}}
{{userEmailAddress}}
{{customText(25)}}
{{customText(25)}}
|
| |
|
|
| |
|
|
| * |
emtricitabine 200 mg/tenofovir alafenamide 25 mg. |
|
| |
FTC, emtricitabine; INSTI, integrase strand transfer inhibitor; TAF, tenofovir alafenamide.
|
References: 1. BIKTARVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2019. 2. Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor [...]. Antimicrob Agents Chemother. 2016;60(12):7086-7097.
|
|
| |
|
|
|
|
